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Turning over or turning around: Hepatic phosphatidylcholine in 
the mouse model for progressive familial intrahepatic cholestasis 
type 3 (PFIC3) 
 
Bruno Stieger, Division of Clinical Pharmacology and Toxicology, Department of Medicine, 
University Hospital, 8091 Zurich, Switzerland 
 
Modern life style in Western societies has lead to an increase of artherosclerosis, the 
consequences of which are presenting a major health care problem. Artherosclerosis 
positively correlates with plasma cholesterol levels, which is determined by dietary 
cholesterol intake, cholesterol biosynthesis and cholesterol excretion. The latter occurs either 
by biosynthesis of bile salts starting from cholesterol in hepatocytes or by cholesterol 
excretion into bile. Biliary cholesterol excretion critically depends on hepatic bile salt and 
phosholipid secretion (1). Biliary phospholipids consist mostly of phosphatidylcholine (PC). 
PC secretion into the canalicular lumen requires the coordinate action of ABCB4/Abcb4 
(human/rodents) (1) and BSEP/Bsep (or ABCB11/Abcb11) (2). The mechanism of biliary PC 
secretion has been worked out with the help of knockout mice defective in functional Abcb4 
and by elucidating the pathophysiologic alterations in patients with inherited human diseases 
progressive familial intrahepatic cholestais (PFIC) type 3 and PFIC2 (or BSEP and MDR3 
deficiency syndrome, respectively) (3). Both, mice with a disrupted Abcb4 gene and humans 
with mutations in the ABCB4 gene are not capable of biliary PC secretion, but display normal 
bile salt secretion. Moreover, the amount of PC secreted into bile is positively correlated with 
the amount of canalicular bile salt secretion, which releases PC from the canalicular 
membrane and subsequently promotes the formation of mixed PC/bile salt micelles. If either 
canalicular bile salt secretion or PC secretion is defective, biliary cholesterol secretion is also 
impaired, due to the lack of a suitable cholesterol acceptor in bile. Hence, ABCB4 may 
indirectly contribute to serum cholesterol homeostasis. 
Abcb4 knockout mice (and patients with PFIC3) have no PC in their bile, but secrete high 
amount of bile salts. These mice develop liver disease with portal inflammation and ductular 
proliferation leading to dysplasia, dysplastic nodules and with increasing age (beginning at an 
age of 4 to 6 months) hepatocellular carcinoma (4). These pathologies are attributed to the 
toxic action of bile salts on the bile duct epithelium as well as to retention of bile salts in 
hepatocytes (5). Along these lines, it was recently reported that patients with PFIC2 having 
bile salt export pump deficiency display an increased risk of hepatobiliary malignancy (6, 7), 
hence supporting the concept that bile salts can act as tumor promoting agents. Taken 
together, studies in Abcb4 knockout mice (and interpretation of pathophysiologic findings 
from patients with PFIC2 and PFIC3) have focused on pathological consequences resulting 
from canalicular secretory defects, while little or no attention has been paid to hepatocellular 
PC metabolism as a cause for liver pathology in situations of absent PC secretion. 
The biosynthesis of phosphatidylcholine occurs either from choline via the CDP-choline 
pathway (or the so-called "Kennedy pathway") or by methylation of 
phosphatidylethanolamine (PE) through phosphatidylethanolamine N-methyl transferase 
(PEMT) (8, 9). Besides being an important lipid component of intracellular and plasma 
membranes in liver 8and all other) cells, PC is secreted via lipoproteins into serum or 
mediated by Abcb4 into bile. In Abcb4 knockout mice, this latter pathway is non-existing, so 
these animals might have an altered PC homeostasis. Interestingly, the total phospholipid 
content of such livers is not different from wild type animals, suggesting an unaltered PC 
content (10, 11). Furthermore, serum lipoprotein content in these mice is also reduced in 
normal and cholestatic conditions, indicating lower phospholipid content associated with 
lipoproteins, which could be due to reduced lipoprotein secretion from the liver (10, 11). 
Finally, the biosynthesis and turnover of PC, e.g. by phosholipase A2 to toxic lysoPC (12) 
may be altered as a consequence of nonfunctional Abcb4. 
In this issue, Baghdasaryan et al. (13) focused on PC metabolism in Abcb4 knockout mice to 
test, whether impaired biliary PC secretion would lead to formation and/or retention of 
abnormal and potentially toxic PC metabolites in liver. To this end, they fed knockout mice 
with a diet enriched in soybean lecithin or with a choline deficient diet and compared these 
animals with knockout mice fed on a control (standard) diet. The key finding of their study is 
that the different feeding regimens did neither alter hepatic, serum nor biliary phospholipids 
nor that toxic PC metabolites were increased. The authors also observed that the soybean 
lecithin diet (additional supply of PC to the liver) decreased serum levels of alkaline 
phosphatase and bilirubin in comparison to knockout mice fed a standard chow. However, 
degree of portal fibrosis as well as hydroxyproline content did not differ among the different 
treated animal groups, indicating no improvement bile ductular damage for the soybean 
lecithin diet. 
Of note, the authors investigated the enzymes involved in PC biosynthesis and found no 
changes in mRNA levels of choline kinase α and β, choline-phosphate cytidyl transferase (or 
phosphocholine transferase) (CT) and of PEMT. Among these enzymes, CT catalyzes the rate 
limiting step of PC biosynthesis. Transcriptional regulation of this enzyme is complex and 
depends on Sp1, but other factors are most likely important, as data from the regulation of this 
enzyme during the cycle suggest (9). In addition to transcriptional regulation, CT exists in a 
soluble or cytosolic, inactive and a membrane bound, active form (8, 9). The translocation of 
CT to membranes is fast and allows a quick response of a cell to the need for PC. Hence, 
while mRNA level of CT in this study was not altered by the different feeding regimens, the 
possibility remains that a shift from the membrane bound to the cytosolic pool of CT occurs 
as a consequence of non-existent canalicular PC secretion, which in turn would down-regulate 
PC biosynthesis. Last but not least, CT is undergoing phosphorylation and may hence be 
subject to extensive posttranscriptional regulation. 
The observation of the soybean lecithin induced reduction in serum liver markers alkaline 
phosphatase and bilirubin is difficult to explain at this moment. Both markers represent the 
the state of health of hepatocytes. Hence the data suggest that in these animals that the state of 
health of hepatocytes may be improved by the soybean lecithin diet. This is supported by the 
reduction of the proliferative activity of hepatocytes in this diet group. Dietary lecithin also 
protects against the negative effects of cholate feeding on livers of Abcb4 knockout mice, 
again supporting a protective role of lecithin in the diet for the liver of these animals (14). The 
direct link between the diet and the health state of hepatocytes in these situations is however 
not evident. While additional components of the diets used in such experiments may exert the 
beneficial effect, soybean lecithin diets could also lead to subtle changes in the relative 
cellular amounts of PC and PE in liver, even though the study of Baghdasaryan et al. (13) 
found no obvious differences in the content of PC and PE in the different diet groups. It can 
however not be ruled out at the moment that the diet regimen could lead to subtle alterations 
in PC and PE content of hepatocellular membranes. These two lipids are asymmetrically 
distributed in membranes, whereby PE is enriched in the cytosolic leaflet of membranes, 
while PC is enriched in the non-cytosolic or luminal leaflet of the membrane. The relative 
transmembrane distribution of these two lipids is essential for a "normal" membrane behavior 
(15). In conclusion, this study has opened a new potential avenue to treat patients with 
cholestatic liver diseases not only with ursodeoxycholic acid, but also by dietary means. 
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